Skip header and navigation

Refine By

4519 records – page 1 of 452.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

[2 vaccine dosages for basic prevention of whooping cough in children over 2 years of age?]

https://arctichealth.org/en/permalink/ahliterature34713
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Publication Type
Article
Date
Jul-10-1996
Author
L. Gothefors
J. Storsaeter
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Date
Jul-10-1996
Language
Swedish
Publication Type
Article
Keywords
Age Factors
Child, Preschool
Denmark
Humans
Immunization Schedule
Pertussis Vaccine - administration & dosage
PubMed ID
8801406 View in PubMed
Less detail

6th Canadian Immunization Conference. Montreal, Quebec, 5 to 8 December, 2004. Oral scientific abstracts.

https://arctichealth.org/en/permalink/ahliterature173326
Source
Can Commun Dis Rep. 2005 Aug 1;31(15):161-7
Publication Type
Conference/Meeting Material
Article
Date
Aug-1-2005
Source
Can Commun Dis Rep. 2005 Aug 1;31(15):161-7
Date
Aug-1-2005
Language
English
French
Publication Type
Conference/Meeting Material
Article
Keywords
Canada
Humans
Immunization
Vaccines - therapeutic use
PubMed ID
16100790 View in PubMed
Less detail

A 10-year follow-up study of tick-borne encephalitis in the Stockholm area and a review of the literature: need for a vaccination strategy.

https://arctichealth.org/en/permalink/ahliterature35021
Source
Scand J Infect Dis. 1996;28(3):217-24
Publication Type
Article
Date
1996
Author
M. Haglund
M. Forsgren
G. Lindh
L. Lindquist
Author Affiliation
Department of Infectious Diseases, Stockholm Country Council, Huddinge Hospital, Sweden.
Source
Scand J Infect Dis. 1996;28(3):217-24
Date
1996
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Aged
Child
Encephalitis, Tick-Borne - complications - epidemiology - immunology
Female
Follow-Up Studies
Headache - complications
Humans
Male
Mental Disorders - complications
Middle Aged
Musculoskeletal Equilibrium
Prevalence
Questionnaires
Sensation Disorders - complications
Seroepidemiologic Studies
Sweden - epidemiology
Vaccination
Abstract
143 people treated for tick-borne encephalitis (TBE) were included in a retrospective follow-up study. Sequelae and epidemiological characteristics in 114 individuals were analysed. The case fatality rate and the prevalence of residual paresis were low, 1.4 and 2.7%, respectively. However, 40 (35.7%) individuals were found to have a postencephalitic syndrome after a median follow-up time of 47 months, and a majority (77.5%) of these were classified as moderate to severe. Various mental disorders, balance and co-ordination disorders and headache were the most frequently reported symptoms. Increasing age was correlated to a longer duration of hospital stay, longer convalescence and increased risk of permanent sequelae. Results from a neuropsychiatric questionnaire showed marked differences between the subjects with sequelae compared to controls. 57% had noticed a tick bite before admission, and 48% were aware of at least one person in their environment who previously had contracted TBE. 79% were permanent residents or visited endemic areas often and regularly. In conclusion, we have found that TBE in the Stockholm area has a low case fatality rate, but gives rise to a considerable number of different neurological and mental sequelae, which justifies vaccination of a defined risk population in endemic areas.
PubMed ID
8863349 View in PubMed
Less detail

The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.

https://arctichealth.org/en/permalink/ahliterature120452
Source
Pediatr Infect Dis J. 2013 Mar;32(3):257-63
Publication Type
Article
Date
Mar-2013

The 16th International Conference on AIDS: will it leave a legacy?

https://arctichealth.org/en/permalink/ahliterature160673
Source
MedGenMed. 2007;9(2):15
Publication Type
Article
Date
2007

[100th anniversary of the National Serum Institute].

https://arctichealth.org/en/permalink/ahliterature188274
Source
Ugeskr Laeger. 2002 Sep 9;164(37):4259
Publication Type
Article
Date
Sep-9-2002
Author
Peter Skinhøj
Source
Ugeskr Laeger. 2002 Sep 9;164(37):4259
Date
Sep-9-2002
Language
Danish
Publication Type
Article
Keywords
Academies and Institutes - history
Communicable Disease Control - history
Denmark
History, 20th Century
Humans
Microbiology - history
Vaccines - history
Notes
Comment On: Ugeskr Laeger. 2002 Sep 9;164(37):4261-512362865
PubMed ID
12362864 View in PubMed
Less detail

110 million dollars vaccine research centre to be built in Saskatoon.

https://arctichealth.org/en/permalink/ahliterature164710
Source
CMAJ. 2007 Mar 13;176(6):751
Publication Type
Article
Date
Mar-13-2007

4519 records – page 1 of 452.